See more : Direct Digital Holdings, Inc. (DRCTW) Income Statement Analysis – Financial Results
Complete financial analysis of CinCor Pharma, Inc. (CINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CinCor Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- First Responder Technologies Inc. (WPNNF) Income Statement Analysis – Financial Results
- Coor Service Management Holding AB (COOR.ST) Income Statement Analysis – Financial Results
- Hapag-Lloyd Aktiengesellschaft (HPGLY) Income Statement Analysis – Financial Results
- Mercato Partners Acquisition Corporation (MPRA) Income Statement Analysis – Financial Results
- Glittek Granites Limited (GLITTEKG.BO) Income Statement Analysis – Financial Results
CinCor Pharma, Inc. (CINC)
About CinCor Pharma, Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.51M | 17.95M | 3.93M |
| General & Administrative | 21.00M | 3.17M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 21.00M | 3.17M | 1.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.51M | 21.13M | 5.14M |
| Cost & Expenses | 42.51M | 21.13M | 5.14M |
| Interest Income | 21.64K | 36.73K | 101.71K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.88M | 1.21M | 171.86K |
| EBITDA | -34.63M | -19.92M | -5.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.51M | -21.13M | -5.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.86M | -1.17M | 101.71K |
| Income Before Tax | -50.37M | -22.30M | -5.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.64K | -36.73K | -101.71K |
| Net Income | -50.35M | -22.26M | -4.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.42 | -0.95 | -0.21 |
| EPS Diluted | -1.42 | -0.95 | -0.21 |
| Weighted Avg Shares Out | 35.42M | 23.49M | 23.49M |
| Weighted Avg Shares Out (Dil) | 35.42M | 23.49M | 23.49M |
The Year's First Three IPOs All Went 'Clunk.' This Is Why.
Three Biotech IPOs Started Trading. Here's How the Stocks Did.
CinCor Pharma's stock opens well above IPO price, then sells off sharply
CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range
2022 IPO Market Kicks Off With 3 Biotechs Set To Trade On Friday
Source: https://incomestatements.info
Category: Stock Reports